Skip to content

Effect of intravenous infusion of different dose of methoxamine on the development of early postoperative cognitive dysfunction in elderly patients and tumor necrosis factor-alpha in the peripheral blood

Effect of intravenous infusion of different dose of methoxamine on the development of early postoperative cognitive dysfunction in elderly patients and tumor necrosis factor-a in the peripheral blood

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-15007607
Enrollment
Unknown
Registered
2015-12-06
Start date
2013-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Cognitive Dysfunction

Interventions

Group C:an equal volume of normal saline
Group M1:After epidural injection, patients received continuous intravenous infusion of Methoxamedrine (2 mcg/kg/min)
Group M2:After epidural injection, patients received continuous intravenous infusion of Methoxamedrine (4 mcg/kg/min)
Group M3:After epidural injection, patients received continuous intravenous infusion of Methoxamedrine (6 mcg/kg/min)

Sponsors

the First Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
75 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Over 75 years old; 2. American Society of Anesthesiology (ASA) II or III; 3. Mini-Mental State Examination (MMSE) score of > 23; 4. Greater than six years of education?Unilateral total hip replacement under epidural anesthesia.

Exclusion criteria

Exclusion criteria: 1. Deviant liver and kidney function; 2. There is an obvious history of neurological diseases or hyperthyroidism; 3. Taking sedative drugs, antidepressants or analgesics; 4. There is a history of drug abuse and alcohol abuse; 5. Obvious impairment of vision and hearing; 6. Electrolyte disturbance; 7. Pathoglycemia; 8. There is a clear infection or respiratory system complication before operation; 9. The second operation.

Design outcomes

Primary

MeasureTime frame
TNF-alpha;MMSE;

Secondary

MeasureTime frame
MAP;CVP;HR;CO;SV;SpO2;The intraoperative total transfusion volume;The intraoperative dosage of ephedrine;The intraoperative and postoperative dosage of ropivacaine;The urine volume of 24 h after operation and in operation;The dosage of postoperative sufentanil ;The incidence of intraoperative pulmonary edema;The incidence of intraoperative hypertension;The incidence of intraoperative hypotension;The incidence of intraoperative tachycardia;The incidence of intraorative bradycardia;The cumulative time of intraorative hypotension;VAS score;BCS score;

Countries

China

Contacts

Public ContactSun Defeng
sdf-yl@163.com+86 18098876191

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 26, 2026